Vestal Point Capital, LP Ascendis Pharma A/S Transaction History
Vestal Point Capital, LP
- $1.4 Trillion
- Q1 2025
A detailed history of Vestal Point Capital, LP transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Vestal Point Capital, LP holds 150,142 shares of ASND stock, worth $24.9 Million. This represents 1.67% of its overall portfolio holdings.
Number of Shares
150,142
Previous 520,000
71.13%
Holding current value
$24.9 Million
Previous $71.6 Billion
67.31%
% of portfolio
1.67%
Previous 4.24%
Shares
6 transactions
Others Institutions Holding ASND
# of Institutions
272Shares Held
61.8MCall Options Held
151KPut Options Held
226K-
Ra Capital Management, L.P. Boston, MA10.3MShares$1.7 Billion33.28% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.48MShares$907 Million4.42% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.22MShares$864 Million13.16% of portfolio
-
Janus Henderson Group PLC London, X04.49MShares$743 Million0.4% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.26MShares$705 Million1.14% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $9.24B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...